Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]NAV4694 PET Imaging in MCI
NCT01812213Phase 2Terminated
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Mar 2013
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flutafuranol in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoint: Incidence of Mild Cognitive Impairment Progression to Alzheimer's Disease at 3 years. Started Mar 2013; status: terminated.
02
Drugs
flutafuranol
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01812213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812213.